


Collaborative Framework for Care and Control of Tuberculosis and Diabetes



International Union Against
Tuberculosis and Lung Disease
Health solutions for the poor



World Health
Organization

Collaborative framework for care and control of tuberculosis and diabetes

**Stop TB Department and
Department of Chronic Diseases and Health Promotion
World Health Organization, Geneva, Switzerland**

and

**The International Union Against Tuberculosis and Lung
Disease, Paris, France**



Collaborative framework for care and control of tuberculosis and diabetes.

WHO/HTM/TB/2011.15

1.Tuberculosis - prevention and control. 2.Tuberculosis - etiology.
3.Tuberculosis - complications. 4.Diabetes complications. 4.Diabetes mellitus
- prevention and control. 5.Health programs and plans. 6.Guidelines. I.World
Health Organization. II.International Union against Tuberculosis and Lung
Disease

ISBN 978 92 4 150225 2

(NLM classification: WF 200)

Provisional collaborative framework, 2011

Expiry date, 2015

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland



Contents

Acknowledgements	iv
Abbreviations	v
Executive summary	vii
1. Introduction	1
1.1 Rationale	1
1.2 Purpose	3
1.3 Target audience	5
2. Framework development process	7
3. Recommended collaborative activities for prevention and care of diabetes and tuberculosis	13
A. Establish mechanisms for collaboration	14
B. Detect and manage tuberculosis in patients with diabetes	19
C. Detect and manage diabetes in patients with tuberculosis	23
4. Indicators for evaluating collaborative activities	26
5. Implementing collaborative activities and evaluating their impact	27
Annexes	28
Annex I. Members of the Guideline Group	28
Annex II. Summary grading of the evidence	30
Annex III. Key research questions for improving prevention, management and care of diabetes and tuberculosis	34
References	35
Support material on the web: Detailed summary of studies included in the systematic reviews (http://www.who.int/tb/publications/2011/en/index.html)	
1. Associations between diabetes and tuberculosis infection, tuberculosis disease and drug-resistant tuberculosis	
2. Associations between diabetes and tuberculosis treatment outcomes	
3. Summary of studies on screening for tuberculosis in diabetes patients and screening for diabetes in tuberculosis patients, and studies on tuberculosis preventive therapy in patients with diabetes	

Acknowledgements

The development of this framework was coordinated by Anthony D. Harries and Knut Lönnroth, who also wrote the first draft. The Guideline Group also consisted of (in alphabetical order): Meghan A Baker, Mauricio Barreto, Nils Billo, Richard Brostrom, Ib Christian Bygbjerg, Martin Castellanos, Saidi Egwaga, Susan Fisher-Hoch, Christie Y. Jeon, Megan B. Murray, Toru Mori, Salah-Eddine Ottmani, Kaushik Ramaiya, Gojka Roglic, Nigel Unwin, Vijay Viswanathan, David Whiting, Lixia Wang and Wenhua Zhao. Annex I lists the professional affiliation and area of technical expertise for each group member.

Declaration of conflict of interests


Dr Vijay Viswanathan declared that he had received financial support for consulting and research within the past three years from the World Diabetes Foundation for a project on preventing diabetes among TB patients. No other member of the group reported any conflicts of interest. Individuals affiliated with the World Diabetes Foundation who attended the expert meeting were not engaged in developing this provisional framework.

Review by date

This provisional collaborative framework is due for revision by 2015.

Abbreviations

DOTS	the basic package that underpins the Stop TB Strategy
HbA1c	glycated haemoglobin
HIV	human immunodeficiency virus
NTP	national tuberculosis control programme
OGTT	oral glucose tolerance test
OR	odds ratio
PHC	primary health care
R	rifampicin
RR	relative risk
TB	tuberculosis
The Union	International Union Against Tuberculosis and Lung Disease
WDF	World Diabetes Foundation
WHO	World Health Organization



预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28669

